Ravidasvir clinical trials
Also written PPI-668 and ASC16.
How each study uses ravidasvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 2
Ascletis Pharmaceuticals Co., Ltd. (6) · Presidio Pharmaceuticals, Inc. (4) · Muhammad Radzi Abu Hassan (1) · Drugs for Neglected Diseases (1) · Pharco Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Danoprevir (4) · Sofosbuvir (2) · ASC18 (1) · Ritonavir (1) · Ribavirin (1) · Telaprevir (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses ravidasvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis CCompletedPhase 2/3Muhammad Radzi Abu HassanNCT04885855Written as Ravidasvir 200mgHow we know
- Strategic Transformation of the Market of HCV TreatmentsStatus unknownPhase 2/3Drugs for Neglected DiseasesNCT02961426Written as sofosbuvir + ravidasvirHow we know
- A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy VolunteersCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT04358523Written as ravidasvir and sofosbuvirHow we know
- Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedPhase 2Ascletis Pharmaceuticals Co., Ltd.NCT03020095Written as RavidasvirHow we know
- Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedPhase 2/3Ascletis Pharmaceuticals Co., Ltd.NCT03362814Written as RavidasvirHow we know
- A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03430830Written as Ravidasvir 50mgHow we know
- Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03020134Written as RavidasvirHow we know
- Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03288636Written as RavidasvirHow we know
- A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4Status unknownPhase 2/3Pharco PharmaceuticalsNCT02371408Written as ravidasvir hydrochlorideHow we know
- Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule FormulationsCompletedPhase 1Presidio Pharmaceuticals, Inc.NCT02258321Written as PPI-668 tabletHow we know
- Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule FormulationsCompletedPhase 1Presidio Pharmaceuticals, Inc.NCT01979484Written as PPI-668 capsuleHow we know
- A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and OmeprazoleCompletedPhase 1Presidio Pharmaceuticals, Inc.NCT01786382Written as PPI-668How we know
- A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1CompletedPhase 1Presidio Pharmaceuticals, Inc.NCT01448200Written as PPI-668How we know
Given beside what is tested · 1 — ravidasvir is usual care or a partner of the new treatment
Codes
What other systems call ravidasvir · ClinicalTrials.gg INT000752
- UNII (FDA) AL3G001BI8RAVIDASVIRConfirmed FDA, Wikidata
- Wikidata Q25101668ravidasvirConfirmed FDA, Wikidata
- NCI Thesaurus C152158RavidasvirOne source FDA
- DrugBank DB15652One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AL3G001BI8 | RAVIDASVIR | Confirmed FDA, Wikidata |
| Wikidata | Q25101668 | ravidasvir | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152158 | Ravidasvir | One source FDA |
| DrugBank | DB15652 | — | One source Wikidata |
Also registered as ravidasvir hydrochloride (UNII HWN7376681).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.